Clostridium difficile is the most important cause of nosocomial infectious diarrhea. The importance of C. difficile-associated diarrhea (CDAD) has been poorly investigated in patients with neutropenia who have hematologic malignancies. A retrospective chart review of all patients treated in the leukemia ward of a university medical center during 1991-2000 determined that 875 courses of myelosuppressive chemotherapy were administered. CDAD occurred in 7.0% of all cycles. In 8.2% of the patients, severe enterocolitis developed. Two patients died while they had diarrhea. However, in no patient was C. difficile infection clinically considered to be the primary cause of death. The response rate to oral metronidazole was 90.9%. These data indicate that C. difficile infection is not rare and should be suspected whenever a hospitalized patient with neutropenia develops diarrhea. Oral metronidazole can be recommended as initial drug of choice for treatment of patients with neutropenia who have hematologic malignancies and CDAD.
for 14 weeks were reported [5] . Other risk factors include recent receipt of cancer chemotherapy [6] and antiviral therapy [7] . After infection, the clinical course ranges from asymptomatic colonization to diarrhea to more severe disease syndromes [2] . Abdominal infections are life-threatening complications for patients with profound neutropenia [8] . Most patients with neutropenia have hematologic malignancies and present with a combination of risk factors for CDAD. The literature provides only few data concerning C. difficile infection occurring in these patients [9] [10] [11] [12] . Therefore, we reviewed the case records for all patients who had CDAD during 1991-2000 in the leukemia ward of our university hospital.
PATIENTS AND METHODS
All 875 consecutive unselected courses of myelosuppressive chemotherapy (with a duration of neutropenia of у5 days) administered from April 1991 through January 2000 to 371 patients treated in the 18-bed leukemia ward of our university medical center were retrospectively screened for the occurrence of sympto- [4] , it was the policy of our institution to reevaluate our high-risk patients during therapy for persistence of C. difficile toxin in stool specimens to obtain additional certainty concerning the success of therapy. According to the recommendations of the American Society for Microbiology [13] , stool filtrates were inoculated onto Vero cells in tissue culture. The cell cultures were screened for cytopathic effects by means of microscopic inspection after incubation periods of 24 h and 48 h. Specimens that induced a cytopathic effect compatible with that typically caused by C. difficile toxin were inoculated onto Vero cells supplemented with antitoxin against Clostridium sordellii toxin (toxin neutralization test).
Neutropenia was defined as a decrease in WBC count to ! cells/L or a decrease in neutrophils to ! cells/ 9 9 1 ϫ 10 0.5 ϫ 10 L. Patients were also included in analysis if C. difficile toxin was detected after the start of chemotherapy that led to neutropenia or within a period of 7 days after the resolution of neutropenia. The diagnosis of severe enterocolitis was made if the patient presented with fever (temperature, у38.5ЊC), at least 1 clinical symptom in the abdomen (e.g., abdominal pain, guarding, ileus, vomiting, diarrhea), and radiographic or ultrasound demonstration of involvement of the bowel. The remaining patients had CDAD diagnosed.
A response was defined as resolution of diarrhea (i.e., return to normal bowel habits) within 14 days of appropriate therapy without deterioration of other abdominal symptoms. Treatment failure was defined as deterioration of other abdominal symptoms, persistence of diarrhea after 14 days of appropriate therapy, or progression to severe enterocolitis. A recurrence (including relapses and early reinfections) was defined as reappearance of diarrhea with detection of C. difficile toxin within 30 days after the end of specific therapy. In the statistical analysis, repeated episodes of CDAD in 1 patient that occurred after 130 days were considered to be independent CDAD episodes and not cases of recurrence. The x 2 test was used for comparisons, when appropriate.
Antimicrobial prophylaxis for patients with neutropenia consisted of mucosal antiseptics, oral amphotericin B, systemic fungal prophylaxis with itraconazole (from September 1994), and oral antibiotic prophylaxis with colistin (200 mg t.i.d.) and trimethoprim-sulfamethoxazole (160 mg/800 mg b.i.d.), until recovery of the neutrophil count or fever requiring iv antimicrobial therapy. Different itraconazole regimens were given as described elsewhere [14] . Oral ciprofloxacin (200 mg/day) was given to a few patients who developed intolerance to trimethoprim-sulfamethoxazole. Prophylactic oral acyclovir was also administered from July 1998 at a dosage of 400 mg b.i.d. Antibiotics administered intravenously during the study period are listed in table 1. Food precautions included omission of uncooked vegetables and unpeeled fruits from the patient's diet. Storage of cooked meals was prohibited completely and storage of other food was restricted to 24 h.
RESULTS

Epidemiology.
From April 1991 through January 2000, 61 independent episodes of CDAD occurred in 53 patients. The Coagulase-negative staphylococci 6
Escherichia coli 4
Streptococcus species 2
Proteus mirabilis 2
Klebsiella pneumoniae 1
Pseudomonas aeruginosa 1 frequency per episode of chemotherapy-related neutropenia was 7.0% (61 episodes of CDAD of 875 episodes of neutropenia). Six patients had 2 episodes of CDAD and 1 patient had 3 episodes. The frequency per patient was 14.3% (53 patients who developed у1 episode of CDAD of 371 patients who received у1 cycle of myelosuppressive chemotherapy). All of these patients who developed diarrhea had been tested for C. difficile toxin in stool specimens. The major clinical characteristics are summarized in table 1. The median duration of neutropenia was 22 days (range, 6-63 days). The median day of neutropenia on which C. difficile toxin was detected was day 10 (range, day 0-52).
The median age of the infected patients was 53 years (range, 18-80 years). Thirty-five patients (57.4%) were male, and 26 (42.6%) were female. Underlying malignancies included acute myeloid leukemia in 43 CDAD episodes (70.5%), acute lymphatic leukemia in 12 episodes (19.7%), blast crisis of chronic myeloid leukemia in 4 episodes (6.6%), and high-grade nonHodgkin's lymphoma in 2 episodes (3.3%). There were no significant differences concerning these parameters in patients with and without CDAD.
In 35 (57.4%) of the 61 CDAD episodes, patients received prior iv antibiotics. The median number of iv antibiotics administered to these patients was 2 (range, 1-7). All of these patients received at least 1 penicillin or cephalosporin antibiotic (table 1). In 25 (41.0%) of the 61 episodes, CDAD developed during oral antibiotic prophylaxis with colistin and trimethoprim-sulfamethoxazole and, in the case of 1 patient (1.6%), with colistin and ciprofloxacin. In 22 CDAD episodes (36.1%), patients had received chemotherapy with high-dose cytarabine (у6 doses of у1.000 mg/m 2 ). Clinical features and laboratory findings. All C. difficile toxin-positive patients had diarrhea, because this symptom initiated the diagnostic test. Complications, such as toxic megacolon, complete bowel obstruction, intestinal perforation, or peritonitis, were not observed. Bacteremia during the presence of symptoms (diarrhea, fever) was detected in 13 (21.3%) of 61 episodes. Bacteremia caused by C. difficile or other anaerobic bacteria was not observed. Further data are shown in table 2.
Treatment and outcome. Two patients (3.3% of 61 episodes) died during the presence of diarrhea as the leading symptom of C. difficile infection. One patient died of pneumonia without detection of a causative pathogen and 1 patient died of asystole of unknown cause. Thirteen other patients (21.3%) died within 30 days after detection of C. difficile toxin. The primary causes of death were pneumonia (6 patients), septic shock (3 patients), invasive fungal infection (2 patients), and refractory leukemia with leukostasis syndrome (2 patients). Although a degree of contribution cannot be excluded, in none of the deaths was C. difficile suspected to be the primary cause of death. None of our patients underwent surgical treatment because of C. difficile infection.
Fifty-seven patient CDAD episodes were evaluable for response to therapy. Two patients who died during diarrhea and 2 patients who had spontaneous resolution of diarrhea after 1 In the remaining 20 episodes, patients received metronidazole as initial therapy either exclusively intravenously (500 mg t.i.d.; 8 patients) or sequentially with oral metronidazole (12 patients), because oral application was not tolerated. Thirteen patients (65%) responded to this therapy. Eleven patients (55%) responded within 6 days. Seven patients (35%) had treatment failure. In 2 patients, diarrhea did not resolve and the clinical condition worsened. In 5 patients (8.2% of 61 episodes), progression to severe enterocolitis occurred (table 4). In 3 of these patients, nonbacterial pathogens (cytomegalovirus, Candida glabrata, Candida krusei) were considered to be the main causes for progression to severe enterocolitis. Two patients died of septic shock that resulted from invasive fungal infection (C. glabrata, C. krusei), and 1 patient died of pneumonia without detection of the causative agent. However, because a contribution of the C. difficile infection to progression and to death cannot be excluded, these patients were classified as having had failure of treatment for C. difficile. There were no significant differences in the proportions of responders up to day 6 of therapy, when patients who had prior iv antibiotics were compared with those who had not, or when patients who had high-dose cytarabine therapy were compared with those who had not.
Two patients had recurrences 9 days and 16 days, respectively, after the end of previous successful therapy with metronidazole (table 3) . Both were treated successfully with oral metronidazole again. Six patients had 2 independent CDAD episodes and 1 patient had 3 episodes. Intervals between independent episodes varied from 5 to 32 weeks.
DISCUSSION
This study is the largest analysis published thus far of CDAD in patients with neutropenia who have hematologic malignancies, and it is the only one that calculates the frequency of this important infectious complication with use of an appropriate number of patients. We observed CDAD in 7.0% of all courses of myelosuppressive chemotherapy. None of our patients died as a direct consequence of C. difficile infection. Most patients presented with a combination of risk factors for CDAD, such as antibiotic therapy [2] , long-term hospitalization [5] , cancer chemotherapy [6] , and antiviral therapy [7] . Patients treated with oral metronidazole showed a response in 90.9% of cases. Only few studies concerning C. difficile infection in similar cohorts of patients are available (table 5) [9] [10] [11] [12] . None of these investigators specified the frequency of CDAD associated with neutropenia, which is a major risk factor for infection in patients undergoing intensive chemotherapy [15] . Correct diagnosis of CDAD in our setting is difficult. On one hand, diarrhea may have many causes, especially cytotoxic chemotherapy. On the other hand, many patients may have clinically irrelevant C. difficile infection. McFarland et al. [16] found that only 37% of patients with nosocomial C. difficile acquisition developed diarrhea. The recommendations of the Society for Healthcare Epidemiology of America advise against testing of asymptomatic patients [4] . Therefore, it was not our intention to detect patients with asymptomatic colonization, and we did not perform culture of stool samples for C. difficile. All diagnoses were made by stool cytotoxin assay, which is the most specific test for CDAD [2] and the most suitable for detection of clinically relevant infection. The frequency of pseudomembranous enterocolitis was not investigated for 2 reasons. First, colonoscopy has a low sensitivity (51%-55%) for detection of CDAD [4] , and second, an increased risk of perforation or bleeding by endoscopic evaluation of the colon should be considered among patients with neutropenia. b-lactam antibiotics known to suppress resident bowel flora and permitting overgrowth of C. difficile [4] were not use for 42.6% of our patients, who had received only oral prophylaxis with colistin and trimethoprim-sulfamethoxazole (or ciprofloxacin for 1 patient) before detection of CDAD. The latter antibiotics normally preserve the resistance to colonization that is maintained by the resident anaerobic bowel flora. Therefore, we suppose that, in these patients, factors other than colistin and trimethoprim-sulfamethoxazole were more likely implicated in the development of CDAD. The occurrence of fever (44%) in our patients was higher than that reported in the literature [17] . This may be explained by simultaneous infections with other microbes, rather than by C. difficile alone, as indicated by positive blood culture results in 21% of our CDAD episodes. However, C. difficile bacteremia could not be observed. This corresponds with findings in the literature, in which C. difficile bacteremia is rarely described. Rampling et al. [10] observed 2 cases. Bodey et al. [18] detected 136 episodes of clostridial bacteremia in patients with cancer during a 12-year period, none of which were caused by C. difficile.
Discontinuation of the offending antibiotic is a general treatment principle [4] . However, this is impossible for most patients with neutropenia because of a high risk of septic complications. Substitution of b-lactam antibiotics with quinolones and aminoglycosides, which are less frequently described as having involvement in CDAD, should be considered [4] . Oral metronidazole (250 mg q.i.d., given for 10 days) is presently recommended as initial therapy [2] . Oral vancomycin (125 mg q.i.d.) is an alternative choice [2] , but it is not superior with regard to the rates of response, relapse, or failure [17, 19] . Furthermore, it is much more expensive, and the development of vancomycin-resistant enterococci may be supported [19] . Our patients showed an overall response to treatment with oral metronidazole of 90.9%. In a large proportion of episodes (81.8%), patients responded within 6 days, which is high but somewhat inferior to the findings of Wenisch et al. [19] and Teasly et al. [17] that oral metronidazole resulted in cure in 94% or 95% of patients, respectively. In these studies, response was defined as resolution of diarrhea within 6 days of specific therapy. We had a lower response rate than did these studies, which may be attributed to the severe immunosuppression of our patients, because patients with neutropenia may need a longer duration of therapy. Furthermore, in some patients, persistence of diarrhea may be incorrectly attributed to C. difficile, when in fact other factors, such as chemotherapy-induced mucosal damage, were causative. This may be supported by the observation that, in all episodes in which diarrhea resolved beyond 6 days of therapy, C. difficile toxin was not longer detectable in a control specimen.
In 20 CDAD episodes, patients tolerated only complete or partial iv application of metronidazole, mostly because of nausea of various causes; 65% of these patients responded. This success rate is not directly comparable to that of patients exclusively treated with oral metronidazole because of a considerable selection bias between these groups. Fecal bactericidal concentrations of metronidazole can be achieved by the iv route [20] . However, the experience is limited and all proven therapies have been with oral regimens [4] . In this context, our data indicate that treatment with iv metronidazole is feasible in patients with neutropenia if oral administration is not possible.
In only 2 episodes (3.3%) did CDAD recur. This is a lower rate than the 5%-30% reported in the literature [4] . Metronidazole alone was used successfully in both episodes. Only in 5 CDAD episodes (8.2%) did severe enterocolitis (according to our definition) develop. In 3 of these patients, Candida species and cytomegalovirus were implicated in progression. The clinical picture was very similar to that of neutropenic enterocolitis, which is a rare but life-threatening complication among patients with neutropenia [8, 21] . However, it is recommended to differentiate between neutropenic enterocolitis and severe enterocolitis caused by C. difficile infection [22] . The lethality of uncomplicated CDAD seems to be very low, even in patients with neutropenia. Although we cannot rule out a degree of contribution of CDAD to death, in none of our patients was C. difficile infection the primary cause of death. This is comparable to the study of Olson et al. [23] , who observed a frequency of lethality of 0.6% among 908 patients, but in contrast to Frost et al. [24] , who reported that 22 (88%) of 25 deaths in Washington state between 1985 and 1996 with a multiplecause-of-death code of 0084 from the International Classification of Diseases, Ninth Revision, cited C. difficile.
We conclude that, for every hospitalized patient with neutropenia who has diarrhea after undergoing myelosuppressive chemotherapy, stool samples should be examined for C. difficile toxin. The recommendation from the literature to use oral metronidazole as initial drug of choice can also be applied to patients with neutropenia who have CDAD. For patients who receive appropriate therapy, morbidity is limited and lethality is low, compared with other common infections in patients with neutropenia.
